BCR - C. R. Bard, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
333.385
-1.115 (-0.333%)
As of 12:40PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close334.500
Open333.920
Bid333.540 x 400
Ask333.690 x 500
Day's Range333.360 - 334.710
52 Week Range218.720 - 337.730
Volume183,842
Avg. Volume513,796
Market Cap24.301B
Beta0.31
PE Ratio (TTM)43.98
EPS (TTM)7.581
Earnings DateJul 24, 2017 - Jul 28, 2017
Forward Dividend & Yield1.04 (0.31%)
Ex-Dividend Date2017-12-07
1y Target Est315.40
Trade prices are not sourced from all markets
  • Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak
    Zacks4 days ago

    Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

    Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.

  • C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017
    Capital Cube10 days ago

    C.R. Bard, Inc. (New Jersey) : BCR-US: Dividend Analysis : December 08th, 2017 (record date) : By the numbers : December 8, 2017

    Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing C.R. Bard, Inc. (New Jersey) with the following peers – Boston Scientific Corporation, Teleflex Incorporated, Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., Medtronic plc, CryoLife, Inc., Hologic, Inc. and CONMED Corporation (BSX-US, TFX-US, BDX-US, ANGO-US, MMSI-US, MDT-US, CRY-US, HOLX-US and CNMD-US). C.R. ... Read more (Read more...)

  • Capital Cube11 days ago

    ETFs with exposure to C.R. Bard, Inc. (New Jersey) : December 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)

  • How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?
    Simply Wall St.15 days ago

    How Does C R Bard Inc’s (BCR) EPS Growth Stack Up Against Industry Performance?

    When C R Bard Inc (NYSE:BCR) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance ofRead More...

  • American City Business Journals18 days ago

    What Jabil's new director signals about the company's future

    Jabil Inc. has tapped a health care industry financial expert for a soon-to-be-vacant seat on its board of directors. Christopher Holland, senior vice president and chief financial officer of C.R. Bard Inc., was nominated to stand for election to the Jabil board in January, a press release said. C.R. Bard (BCR) is a Murray Hill, New Jersey-based medical technology firm.

  • GlobeNewswire19 days ago

    Market Trends Toward New Normal in Cloudera, C.R. Bard, Jabil Circuit, Valero Energy, Navient, and Interpace Diagnostics Group — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 29, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cloudera, ...

  • Capital Cube21 days ago

    ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)

  • 3 Top Diabetes Stocks to Buy Now
    Motley Fool21 days ago

    3 Top Diabetes Stocks to Buy Now

    The diabetes market is growing. And these stocks are poised to grow with it.

  • Paul Tudor Jones: The Global Macro Trader
    GuruFocus.com23 days ago

    Paul Tudor Jones: The Global Macro Trader

    The guru hit home run after home run in the 20 years ending in 2007, but the last 10 years suggest that tape reading may not be an enduring strategy

  • PR Newswirelast month

    BD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines

    "Today's announcement of our intent to divest two product lines is another step forward in the regulatory review process of BD's planned acquisition of Bard," said Vincent A. Forlenza, chairman and CEO of BD.

  • Capital Cubelast month

    ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)

  • ACCESSWIRElast month

    Earnings Review and Free Research Report: C.R. Bard’s Revenue Grew 5%; Adjusted EPS Increased 14.3%

    Research Desk Line-up: DENTSPLY SIRONA Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on C.R. Bard, Inc. (NYSE: BCR ...

  • ACCESSWIRElast month

    Corporate News Blog - Medical Technology Company Pulse Biosciences Announces Changes to its Board

    Research Desk Line-up: C. R. Bard Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pulse ...

  • Capital Cube2 months ago

    ETFs with exposure to C.R. Bard, Inc. (New Jersey) : November 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)

  • C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017
    Capital Cube2 months ago

    C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 30, 2017

    Categories: Yahoo FinanceGet free summary analysis C.R. Bard, Inc. (New Jersey) reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of C.R. Bard, Inc. (New Jersey) – Boston Scientific Corporation, AngioDynamics, Inc. and Merit Medical Systems, Inc. (BSX-US, ANGO-US and MMSI-US) that have also reported for this ... Read more (Read more...)

  • Associated Press2 months ago

    C.R. Bard beats 3Q profit forecasts

    The Murray Hill, New Jersey-based company said it had net income of $1.25 per share. Earnings, adjusted for one-time gains and costs, came to $3.02 per share. The results beat Wall Street expectations. ...

  • Business Wire2 months ago

    Bard Announces Third Quarter Results

    C. R. Bard, Inc. today reported 2017 third quarter financial results. The company has included supplemental financial data on its website related to this earnings release.

  • EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
    Zacks2 months ago

    EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?

    Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.

  • PR Newswire2 months ago

    BD Statement On European Commission Conditional Clearance Of Bard Acquisition

    "We continue to make good progress on the Bard acquisition and the conditional clearance from the European Commission is a positive step forward," said Vincent A. Forlenza, chairman and CEO of BD. "As expected, we have committed to divesting certain assets associated with our soft tissue core needle biopsy product line, which we acquired with CareFusion, to satisfy the conditions to closing requested by the European Commission.

  • Can CR Bard (BCR) Spring a Surprise This Earnings Season?
    Zacks2 months ago

    Can CR Bard (BCR) Spring a Surprise This Earnings Season?

    We believe that the growing adoption of the company's flagship Lutonix drug coated-balloon will result in improved performance for CR Bard (BCR) in Q3.

  • Reuters2 months ago

    EU mergers and takeovers (Oct 16)

    The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Swiss food company Nestle to acquire sole control of Beverage ...

  • Business Wire2 months ago

    Bard Declares Quarterly Dividend

    The Board of Directors of C. R. Bard, Inc. today declared a regular quarterly dividend of 26 cents per share on Bard's common stock. In connection with the pending merger with Becton, Dickinson & Company, the quarterly dividend will be payable on December 29, 2017 to shareholders of record at the close of business on December 8, 2017.

  • C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : September 18, 2017
    Capital Cube3 months ago

    C.R. Bard, Inc. (New Jersey) breached its 50 day moving average in a Bearish Manner : BCR-US : September 18, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for C.R. Bard, Inc. (New Jersey). More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Market Realist3 months ago

    BD Stock Fell 2.7% on September 13: Should Investors Worry?

    Becton, Dickinson and Company (BDX) closed at $196.62 on September 13, 2017.